Abstract
Although anti-PD-1 and anti-CTLA-4 based immune checkpoint blockade (ICB) has represented a turning point in cancer care, clinical responses are observed only in a fraction of cancer patients. Most research focuses on the identification of additional inhibitory receptors restraining the anti-tumor functions of CD8+ T cells. By contrast, herein, we found that loss of the activating receptor CD226 (DNAM-1) was a critical mechanism affecting CD8+ T cell responsiveness to TCR stimulation. Using cancer patients’ samples and preclinical mouse models, we discovered that dysfunctional CD226-negative CD8+ T cells progressively accumulated in the tumor microenvironment through a mechanism involving the T-box transcription factor Eomesodermin (EOMES). More importantly, we demonstrated that CD226-negative tumor infiltrating lymphocytes had reduced anti-tumor functions and failed to respond to ICB. Altogether, our results revealed that CD226 loss is a critical immune escape mechanism restraining CD8+ T cell function and potentially affecting the therapeutic efficacy of cancer immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.